TRP_1170x120_3-8-19

Eli Lilly

Lilly Diabetes Center established at Indiana University

Lilly Diabetes Center established at Indiana University

INDIANAPOLIS — Eli Lilly and Company and the Indiana Bioscience Research Institute (IBRI), in collaboration with Indiana University School of Medicine, have created the Lilly Diabetes Center of Excellence (LDCE), which aims to establish a nexus of strategically aligned basic diabetes research operations in Indianapolis. The LDCE will recruit high-potential and established principal investigators (PIs) who aim to pursue

Eli Lilly names Anne White to run Oncology division

Eli Lilly names Anne White to run Oncology division

INDIANAPOLIS — Eli Lilly Oncology will have a new president at the helm of the division. Industry veteran Anne White has been tapped to lead the division beginning Sept. 1. She replaced Sue Mahoney, whose last day with the company is today. White is currently the vice president of portfolio management of Chorus and Next Generation Research &

Lilly presents new diabetes data at ADA session

Lilly presents new diabetes data at ADA session

ORLANDO, Fla. — Eli Lilly’s ultra rapid lispro (URLi) led to improved and sustained blood sugar control after meals in people with type 1 and type 2 diabetes, according to results from three phase 1b studies evaluating URLi compared to Humalog. URLi is Lilly’s novel mealtime insulin currently in phase 3 development. The data was presented in

Lilly to acquire ARMO BioSciences

Lilly to acquire ARMO BioSciences

INDIANAPOLIS and REDWOOD CITY, Calif. — Eli Lilly and Company and ARMO BioSciences, Inc. announced a definitive agreement for Lilly to acquire ARMO for $50 per share, or approximately $1.6 billion, in an all-cash transaction. ARMO BioSciences is a late-stage immuno-oncology company that is developing a pipeline of novel, proprietary product candidates designed to activate

FDA recommends the approval of Baricitinib 2mg

FDA recommends the approval of Baricitinib 2mg

INDIANAPOLIS — Eli Lilly and Incyte Corp.  announced that the U.S. Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommended approval of the 2-mg dose of baricitinib, a once-daily oral medication for the treatment of moderately-to-severely active rheumatoid arthritis (RA) for adult patients who have had an inadequate response or intolerance to methotrexate. While the

Study to probe Jardiance effects on kidney disease

Study to probe Jardiance effects on kidney disease

RIDGEFIELD, Conn. and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly and Co.  yesterday announced an academic collaboration with the University of Oxford to investigate the effects of Jardiance on the progression of kidney disease and the occurrence of cardiovascular death, in adults with established chronic kidney disease with and without diabetes. EMPA-KIDNEY will be independently conducted, analyzed and reported by the Medical

Former Lilly CFO to head CVS Caremark

Former Lilly CFO to head CVS Caremark

NEW YORK — CVS Health has named former Eli Lilly and Co. chief financial officer Derica Rice as president of its CVS Caremark pharmacy benefit management unit. Plans call for Rice to take the helm at CVS Caremark on March 30, CVS said late Tuesday. The appointment was earlier reported by The Wall Street Journal.

Trump makes cutting high drug prices a priority

Trump makes cutting high drug prices a priority

WASHINGTON — In his first State of the Union speech, President Donald Trump renewed his pledge to reduce prescription drug prices, days after a former big pharma executive was sworn in as Secretary of Health and Human Services. Trump had stunned the pharmaceutical industry during his 2016 campaign by declaring that drug manufacturers were “getting

Senate confirms Alex Azar as HHS secretary

Senate confirms Alex Azar as HHS secretary

WASHINGTON — Former Eli Lilly and Co. executive Alex Azar has been confirmed by the Senate as the new secretary of the U.S. Department of Health & Human Services (HHS). Nominated for the HHS secretary post in November by President Donald Trump, Azar was approved by the Senate on Wednesday in a 55-43 vote, mainly

Senators grill HHS nominee Alex Azar on cutting drug costs

Senators grill HHS nominee Alex Azar on cutting drug costs

WASHINGTON — Alex Azar, a former pharmaceutical executive named by President Trump to be the next Health and Human Services secretary, told senators at a full committee nomination hearing that making prescription drugs more affordable would be one of his top priorities. “Drug prices are too high,” Azar said to the Senate health committee at

Former Lilly exec Alex Azar tabbed to head HHS

Former Lilly exec Alex Azar tabbed to head HHS

WASHINGTON — Biopharmaceutical industry executive Alex Azar has been nominated as secretary of the U.S. Department of Health and Human Services (HHS) to fill the post vacated by Tom Price. Azar is currently founder and chairman of Seraphim Strategies LLC, an Indianapolis-based consultancy focused on the biopharma and health insurance industries, including biopharmaceutical sales, marketing, pricing,

Eli Lilly earmarks funds for insulin facility upgrade

Eli Lilly earmarks funds for insulin facility upgrade

INDIANAPOLIS — Eli Lilly and Co. plans to invest $72 million in an insulin manufacturing project at one of its Indianapolis facilities. Eli Lilly said the investment will be used to replace a current insulin vial-filling line. The move also stands to enable the company to meet rising demand for its insulins — including Humalog

Eli Lilly releases Humalog Junior KwikPen

Eli Lilly releases Humalog Junior KwikPen

INDIANAPOLIS — Eli Lilly and Co. has rolled out to pharmacies the Humalog Junior KwikPen, which the company describes as the only prefilled, disposable half-unit insulin pen. Humalog Junior KwikPen (insulin lispro injection 100 units/ml) is lighter and shorter than other half-unit insulin pens and provides a diabetes treatment option for people who prefer a

Eli Lilly to acquire CoLucid for $960 million

Eli Lilly to acquire CoLucid for $960 million

INDIANAPOLIS — Eli Lilly and Co. plans to buy CoLucid Pharmaceuticals Inc., maker of a promising migraine medication, for about $960 million in cash. Cambridge, Mass.-based CoLucid is currently in development with lasmiditan tablets, indicated for acute treatment of migraine, and has completed the first of two Phase 3 trials. A data read-out for the